Abstract
Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF). Phase III trials have compared each of these agents to warfarin. Dabigatran was more efficacious than warfarin in reducing the risk of stroke when given at a dose of 150?mg BID to patients with NVAF. Rivaroxaban 20?mg QD was superior to warfarin in on-treatment analysis. Apixaban 5?mg BID was also found to be superior to warfarin in reducing stroke in NVAF patients. Of note, the rate of hemorrhagic stroke was much smaller in the patients treated with NOAC than those with warfarin. NOAC offer a good therapeutic option for prevention of stroke in NVAF patients.
| Original language | English |
|---|---|
| Pages (from-to) | 992-993 |
| Number of pages | 2 |
| Journal | Clinical Neurology |
| Volume | 53 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Dec 1 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Clinical Neurology
Cite this
Evidence of novel oral anticoagulants (NOAC). / Kitazono, Takanari.
In: Clinical Neurology, Vol. 53, No. 11, 01.12.2013, p. 992-993.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evidence of novel oral anticoagulants (NOAC)
AU - Kitazono, Takanari
PY - 2013/12/1
Y1 - 2013/12/1
N2 - Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF). Phase III trials have compared each of these agents to warfarin. Dabigatran was more efficacious than warfarin in reducing the risk of stroke when given at a dose of 150?mg BID to patients with NVAF. Rivaroxaban 20?mg QD was superior to warfarin in on-treatment analysis. Apixaban 5?mg BID was also found to be superior to warfarin in reducing stroke in NVAF patients. Of note, the rate of hemorrhagic stroke was much smaller in the patients treated with NOAC than those with warfarin. NOAC offer a good therapeutic option for prevention of stroke in NVAF patients.
AB - Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF). Phase III trials have compared each of these agents to warfarin. Dabigatran was more efficacious than warfarin in reducing the risk of stroke when given at a dose of 150?mg BID to patients with NVAF. Rivaroxaban 20?mg QD was superior to warfarin in on-treatment analysis. Apixaban 5?mg BID was also found to be superior to warfarin in reducing stroke in NVAF patients. Of note, the rate of hemorrhagic stroke was much smaller in the patients treated with NOAC than those with warfarin. NOAC offer a good therapeutic option for prevention of stroke in NVAF patients.
UR - http://www.scopus.com/inward/record.url?scp=84891789246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891789246&partnerID=8YFLogxK
U2 - 10.5692/clinicalneurol.53.992
DO - 10.5692/clinicalneurol.53.992
M3 - Article
VL - 53
SP - 992
EP - 993
JO - Clinical Neurology
JF - Clinical Neurology
SN - 0009-918X
IS - 11
ER -